Hongbo Lu - Sep 12, 2024 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role: Director
Signature: Hongbo Lu By: /s/ Hongbo Lu
Stock symbol: TERN
Transactions as of: Sep 12, 2024
Transactions value $: $4,999,995
Form type: 4
Date filed: 9/17/2024, 07:48 PM
Previous filing: Jul 2, 2024
Next filing: Sep 17, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TERN	Common Stock	Purchase	$2M	+190K		$10.50	190K	Sep 12, 2024	See footnote	F1
transaction	TERN	Common Stock	Purchase	$3M	+286K	+150%	$10.50	476K	Sep 12, 2024	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2	The reported securities are owned directly by NEXTBio Opportunity Adapt LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital Opportunity Adapt GP, LLC, the managing member of NEXTBio Opportunity Adapt LLC, and (ii) Hongbo Lu, a managing member of NEXTBio Capital Opportunity Adapt GP, LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Content

The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

The reported securities are owned directly by NEXTBio Opportunity Adapt LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital Opportunity Adapt GP, LLC, the managing member of NEXTBio Opportunity Adapt LLC, and (ii) Hongbo Lu, a managing member of NEXTBio Capital Opportunity Adapt GP, LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.